Notably, 3 out of 5 patients with NSCLC harboring KRAS or NRAS driver mutations responded to patritumab deruxtecan in another trial, despite the small number of cases evaluated [41]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.